PMA device
Sinovial (Sodium Hyaluronate 0.8%)
Ibsa Institut Biochimique SA · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision May 9, 2014, newest May 9, 2014Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
4
Naming "Sinovial"
MAUDE reports
1
Brand "Sinovial", since 2015
PubMed studies
66
Mentioning "Sinovial"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sinovial (Sodium Hyaluronate 0.8%)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P110005 · Decided May 9, 2014 · 1,184 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Sinovial", any status and sponsor, newest update first.
- Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2)Pivotal-lookingCompleted
LabrhaNot on our public-company list
NCT05978180 · 252 participants · Start Oct 18, 2023 · Primary completion Nov 13, 2025
Device: Medical Device : HO-1; Medical Device : HS-3 and 1 more · For: Knee Osteoarthritis
Sites: Annecy, France; Arnas, France; Bagnols-sur-Cèze, France · 35 sites in all
- A Study to Evaluate the Clinical Performance and Safety of an Intra-articular Hyaluronic Acid in Knee OsteoarthritisPivotal-lookingCompleted
IBSA Institut Biochimique SANot on our public-company list
NCT03200288 · 692 participants · Start Jun 29, 2017 · Primary completion Jun 27, 2018
Device: HL-01: high and low molecular weight hyaluronic acid; Placebo · For: Knee Osteoarthritis
Sites: Liège, Belgium; Bad Doberan, Germany; Berlin, Germany · 31 sites in all
- Comparison of the Efficacy of Intra-articular Hybrid Hyaluronic Acid and Steroid in Patients With RizoarthrosisStatus unknown
University of SienaAcademic, hospital or other
NCT03200886 · 100 participants · Start May 24, 2017 · Primary completion May 31, 2017
Device: Sinovial H-L · For: Osteoarthritis Thumb
Sites: Siena, Italy
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sinovial", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- SINOVIALInjury
3008280916-2020-00218 · Received Apr 20, 2020 · Event dated May 17, 2019
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Erythema; Hypoesthesia; Malaise
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Sinovial"[tiab]. The summary above synthesizes these.
- [Synovial fluid cytodiagnosis].
Martínez Girón R, Martínez Torre S · Rev Esp Patol · 2020Review
- Radiological manifestations of synovial sarcoma.
Mazza Rapagna AM, Bas Alcolea P, Martínez Arnau N, et al. · Radiologia (Engl Ed) · 2025
- [Primary breast synovial sarcoma].
Alfaro-Cervelló C, Burgués O · Rev Esp Patol · 2018Case Reports
- Increasing Concentration of Sinovial: Effect on Cartilage Protection in a Rabbit ACLT Model.
Boissier P, Mainil-Varlet P, Mautone GR · Cartilage · 2021Research Support, Non-U.S. Gov't
- [Diagnosis: synovial fluid analysis].
Gallo Vallejo FJ, Giner Ruiz V · Aten Primaria · 2014English Abstract
- Cholinergic synovitis: Description of four cases.
Guillén Astete C, Zamorano Serrano M, Luque Alarcón M · Reumatol Clin (Engl Ed) · 2021Case Reports
- Comparison of three treatment protocols with intra-articular low or intermediate molecular weight hyaluronic acid in early symptomatic knee osteoarthritis.
Galluccio F, D'Angela D, Polistena B, et al. · Ther Adv Musculoskelet Dis · 2021
- Olfactory groove monophasic sinovial sarcoma and von Recklinghausen's disease: A case report and literature review.
Nery B, de Alencar Neto JF, Melo LRDS, et al. · Surg Neurol Int · 2023Case Reports
- Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial(®)) vs hylan G-F20 (Synvisc(®)) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study.
Pavelka K, Uebelhart D · Osteoarthritis Cartilage · 2011Clinical Trial, Phase III, Comparative Study
- An update on the study of synovial fluid in the geriatric patient.
Fernández-Torres J, Ilizaliturri-Sánchez V, Martínez-Flores K, et al. · Reumatol Clin (Engl Ed) · 2024
- Can hybrid hyaluronic acid represent a valid approach to treat rizoarthrosis? A retrospective comparative study.
Tenti S, Pascarelli NA, Giannotti S, et al. · BMC Musculoskelet Disord · 2017Comparative Study, Observational Study
- Effect of Sinovial High-Low® injections in trapeziometacarpal osteoarthritis.
Bartoloni E, Luccioli F, La Paglia GMC, et al. · Clin Exp Rheumatol · 2019Letter
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.